The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer

Jong Woo Lee(Yale Cancer Center), Ja Seok Koo(The University of Texas MD Anderson Cancer Center)
Journal of Thoracic Oncology
February 13, 2019
Cited by 84


Related Papers